Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupLJUIF 86 Median PS Value is $0.74 as of Jul. 27, 2026, which is 6% below its 10-year median of 0.79. GuruFocus rates LJUIF with a GF Score™ of 86/100 and a GF Value™ of $0.51. The stock has 8 warning signs investors should review. Among 545 Drug Manufacturers companies, SSY Group ranks better than 78.53% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. SSY Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.182. SSY Group's 10-Year median PS Ratio is 4.0659. Therefore, the Median PS Value for today is $0.74.
As of today (2026-07-27), SSY Group's share price is $0.40255. SSY Group's Median PS Value is $0.74. Therefore, SSY Group's Price to Median PS Value for today is 0.54.
The historical rank and industry rank for SSY Group's Median PS Value or its related term are showing as below:
LJUIF'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54 Med: 0.79 Max: 1.59
Current: 0.54
During the past 13 years, the highest Price to Median PS Value of SSY Group was 1.59. The lowest was 0.54. And the median was 0.79.
LJUIF's Price-to-Median-PS-Value is ranked better than 78.53% of 545
companies
in the Drug Manufacturers industry
Industry Median: 0.86
vs LJUIF: 0.54
SSY Group (OTCPK:LJUIF) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
SSY Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.40255
/
0.74
=
0.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group Median PS Value Related Terms
SSY Group Median PS Value Historical Data
* Premium members only.
The historical data trend for SSY Group's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where SSY Group's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.0659.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SSY Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.182.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (LJUIF) has a Median PS Value of $0.74 as of Jul. 27, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on SSY Group and its competitors. This is near median its historical median of 0.79. Over the past decade, SSY Group's Median PS Value has ranged from 0.54 to 1.59. According to the industry distribution chart, SSY Group ranks #117 out of 545 companies in the Drug Manufacturers industry, placing it in the top 21.5%.
Is SSY Group's Median PS Value too high?
SSY Group's current Median PS Value of $0.74 is near median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 1.59. The Drug Manufacturers industry median Median PS Value is 0.86. SSY Group's value of $0.74 is 14% below this industry median. Based on the distribution chart, SSY Group ranks #117 out of 545 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, SSY Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #117 out of 545 companies for Median PS Value. This places SSY Group in the top 22% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.86. SSY Group's value of $0.74 is 14% below this benchmark. Historically, SSY Group's own Median PS Value has ranged from 0.54 to 1.59 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 0.86, SSY Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 545 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Median PS Value of $0.74 is 14% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Median PS Value is $0.74, which is near median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current Median PS Value of $0.74. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.1% below its estimated fair value. The current Median PS Value is $0.74, which is near median its 10-year median of 0.79 and 14% below the Drug Manufacturers industry median of 0.86. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For SSY Group (LJUIF), the current Median PS Value is $0.74 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.
Key valuation signals for LJUIF:
Median PS Value: $0.74 (near median its 10-year median of 0.79)
GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
Industry Position: 14% below the Drug Manufacturers median (#117 of 545)
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for LJUIF
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
